| GTO ID | GTC2353 |
| Trial ID | NCT04382898 |
| Disease | Prostate Cancer |
| Therapy | mRNA vaccine |
| Treatment | BNT112 |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer |
| Year | 2019 |
| Country | United States|Germany|Hungary|United Kingdom |
| Company sponsor | BioNTech SE |
| Other ID(s) | RN5609C00|2018-004321-86 |
| Vector information | |||
|
|||
| Cohort1: BNT112 | |||||
|
|||||
| Cohort2: BNT112_cemiplimab | |||||
|
|||||